177 related articles for article (PubMed ID: 17094430)
1. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
Jiang H; Lu J; Ji J
Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
[TBL] [Abstract][Full Text] [Related]
3. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
4. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
5. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Wettergren Y; Carlsson G; Odin E; Gustavsson B
Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
[TBL] [Abstract][Full Text] [Related]
6. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
7. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
8. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Carlsson G; Odin E; Gustavsson B; Wettergren Y
Cancer Chemother Pharmacol; 2014 Oct; 74(4):757-63. PubMed ID: 25102934
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
10. Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity.
Kobuchi S; Akutagawa M; Ito Y; Sakaeda T
Biopharm Drug Dispos; 2019 Jan; 40(1):44-48. PubMed ID: 30592773
[TBL] [Abstract][Full Text] [Related]
11. A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer.
César IC; Cunha-Júnior GF; Duarte Byrro RM; Vaz Coelho LG; Pianetti GA
Ther Drug Monit; 2012 Feb; 34(1):59-66. PubMed ID: 22210098
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
J Pharm Sci; 2013 Jun; 102(6):2056-2067. PubMed ID: 23592368
[TBL] [Abstract][Full Text] [Related]
13. Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
Biol Pharm Bull; 2013; 36(6):907-16. PubMed ID: 23575271
[TBL] [Abstract][Full Text] [Related]
14. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
Nakamura A; Kikuchi K; Ohishi T; Masuike T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
[TBL] [Abstract][Full Text] [Related]
15. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Jacobs BA; Rosing H; de Vries N; Meulendijks D; Henricks LM; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jul; 126():75-82. PubMed ID: 27179185
[TBL] [Abstract][Full Text] [Related]
18. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
19. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
20. Indirect assessment of dihydropyrimidine dehydrogenase activity in cats.
Saba CF; Schmiedt CW; Freeman KG; Edwards GL
Vet Comp Oncol; 2013 Dec; 11(4):265-71. PubMed ID: 24007333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
